APA (7th ed.) Citation

DeTemple, V., Kaatz, M., Stockfleth, E., Scheel, C., Angela, Y., Gutzmer, R., . . . Tomsitz, D. (2025). Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma. European journal of cancer, 225, . https://doi.org/10.1016/j.ejca.2025.115590

Chicago Style (17th ed.) Citation

DeTemple, Viola, et al. "Real-world Experience with First- Versus Second-line Cemiplimab for Advanced Basal Cell Carcinoma." European Journal of Cancer 225 (2025). https://doi.org/10.1016/j.ejca.2025.115590.

MLA (9th ed.) Citation

DeTemple, Viola, et al. "Real-world Experience with First- Versus Second-line Cemiplimab for Advanced Basal Cell Carcinoma." European Journal of Cancer, vol. 225, 2025, https://doi.org/10.1016/j.ejca.2025.115590.